ACADIA Pharmaceuticals (ACAD) vs Tarsus Pharmaceuticals (TARS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tarsus Pharmaceuticals (TARS) has outperformed ACADIA Pharmaceuticals (ACAD) over the past year, gaining 7.6% versus a loss of 8.8%. Over five years, TARS leads with a +158.1% price change compared with +12.2% for ACAD. ACADIA Pharmaceuticals is the larger company by market cap ($3.35 billion vs $3.34 billion), about 1.0 times the size, while Tarsus Pharmaceuticals is growing revenue faster (+146.7% vs +11.9%).
ACADIA Pharmaceuticals converts more of its revenue into profit, with a net margin of 36.5% versus -14.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACAD | TARS |
|---|---|---|
| Share price | $19.42 | $71.48 |
| Market cap | $3.35B | $3.34B |
| 1-day change | -1.19% | -2.90% |
| YTD return | -26.43% | -10.10% |
| 1-year return | -8.77% | +7.59% |
| 5-year return | +12.22% | +158.10% |
| P/E ratio (TTM) | 8.71 | — |
| Forward P/E | 21.85 | — |
| EPS (TTM) | $2.23 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.07B | $451.36M |
| Revenue growth (YoY) | +11.87% | +146.71% |
| Net income (latest FY) | $391.00M | $-66.42M |
| Gross margin | 91.69% | — |
| Operating margin | 9.78% | -15.72% |
| Net margin | 36.49% | -14.72% |
| 52-week high | $30.96 | $91.53 |
| 52-week low | $19.32 | $53.89 |
| Distance from 52-week high | -37.29% | -21.91% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +65.64% | +39.21% |
| Average volume | 1.84M | 894.35K |
| Shares outstanding | 172.31M | 46.79M |
| Employees | 796 | 370 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TARS has outperformed ACAD by 16.4 percentage points over the past year.
- ACADIA Pharmaceuticals is more profitable, keeping 36.5 cents of every revenue dollar as net income versus -14.7 cents for Tarsus Pharmaceuticals.
- Tarsus Pharmaceuticals grew revenue faster in its latest fiscal year (+146.71% vs +11.87%).
About ACADIA Pharmaceuticals
ACAD stock →ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Health Care · Biotechnology: Pharmaceutical Preparations · 796 employees
About Tarsus Pharmaceuticals
TARS stock →Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 370 employees
ACAD vs TARS FAQ
Which is bigger, ACADIA Pharmaceuticals or Tarsus Pharmaceuticals?
ACADIA Pharmaceuticals (ACAD) is larger, with a market capitalization of $3.35B compared with $3.34B for Tarsus Pharmaceuticals (TARS).
Which stock has performed better over the past year, ACAD or TARS?
TARS returned +7.59% over the past 12 months, compared with -8.77% for ACAD (price return, excluding dividends). Past performance does not predict future results.
Are ACADIA Pharmaceuticals and Tarsus Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for ACADIA Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for Tarsus Pharmaceuticals.